论文部分内容阅读
目的探究恩替卡韦治疗慢性重症乙型肝炎的临床疗效。方法 68例慢性重症乙型肝炎分为对照组和观察组,每组34例。对照组患者接受综合治疗,观察组患者则在综合治疗的基础上接受恩替卡韦治疗。比较两组肝功能指标及临床疗效。结果观察组白蛋白(ALB)高于对照组,谷丙转氨酶(ALT)及凝血酶原时间(PT)低于对照组(P<0.05)。观察组治疗总有效率(91.18%)明显优于对照组(64.71%)(P<0.05)。结论恩替卡韦治疗慢性重症乙型肝炎有利于改善患者的肝功能,提高治疗效果,值得推广。
Objective To investigate the clinical efficacy of entecavir in the treatment of chronic severe hepatitis B Methods 68 cases of chronic severe hepatitis B were divided into control group and observation group, 34 cases in each group. Patients in the control group received comprehensive treatment and patients in the observation group received entecavir treatment on the basis of comprehensive treatment. The liver function indexes and clinical effects were compared between the two groups. Results ALB in the observation group was higher than that in the control group, while ALT and PT were lower than those in the control group (P <0.05). The total effective rate of observation group (91.18%) was significantly better than that of control group (64.71%) (P <0.05). Conclusion Entecavir treatment of chronic severe hepatitis B is beneficial to improve the patient’s liver function and improve the therapeutic effect, it is worth promoting.